#USA #Miami #Immorta Bio #Longevity Science #Howard Brooks

Immorta Bio Enhances Its Board of Directors with Industry Expert Howard Brooks

Immorta Bio Inc., pioneering the science of longevity and focused on treating the diseases associated with aging, has announced a significant addition to its Board of Directors: Howard Brooks. Previously a partner at Ernst & Young specializing in Health Sciences, Brooks joins at a pivotal moment for the company as it seeks to advance its innovative solutions for aging-related health issues.

A Wealth of Experience in Healthcare

Howard Brooks brings over 30 years of rich experience in advising healthcare and biotechnology organizations. His background includes oversight in corporate strategy, financial management, and governance. During his tenure at EY, he served as the Americas Health Sciences Leader, guiding various companies through complex healthcare landscapes. His appointment promises to strengthen Immorta Bio's governance and strategic direction, especially as the company moves forward in clinical development and capital market engagements.

Brooks' role is not just one of oversight; it includes advocating for Immorta Bio's mission, which is to transform how we treat aging, effectively restructuring it as a public health issue. He will also act as a strategic ambassador, fostering connections with investors and partners critical to the company’s growth trajectories.

Immorta Bio's Dual-Platform Approach

At the heart of Immorta Bio's innovation is its dual-platform strategy which combines two pioneering approaches: SenoVax™ and StemCellRevivify™. SenoVax™ is a senolytic immunotherapy designed to eliminate senescent cells—those that contribute to the aging process and associated diseases. Meanwhile, StemCellRevivify™ focuses on rejuvenating cellular function to restore youthful biological processes. This two-pronged approach represents a significant leap forward in longevity science, targeting not just the symptoms of aging but its underlying causes.

According to Dr. Boris Reznik, CEO of Immorta Bio, Brooks' expertise is exceptionally timing as the company strives toward clinical trials and aims to establish connections for future financing. Reznik states, "Howard's appointment significantly strengthens our Corporate Board at a pivotal moment for the Company. His extensive governance experience in the healthcare sector will be hard to match and will support our long-term objectives."

The Potential Impact of the Appointment

Brooks' board position enhances not only governance but also the overall strategic capacity of Immorta Bio as it prepares for significant clinical advancements. His prior service on multiple healthcare boards and his qualifications as a financial specialist equip him well for the duties ahead, which include compliance, audit, and risk oversight. He joins Russell Kaufman, who notably has a storied history in the medical research sector as another external board member.

With Brooks on board, Immorta Bio is better positioned to tackle the complexities of clinical development. His wealth of knowledge and network within the industry will be vital as the company pushes the boundaries of how we understand and treat aging. Brooks expressed his enthusiasm for this new chapter, stating, "Immorta Bio is addressing aging at its biological roots, which can fundamentally change how we think about disease. I am honored to join the Corporate Board and to serve as a fiduciary, strategic advisor, and ambassador for the Company."

As Immorta Bio continues its quest to enhance healthspan and lifespan, the contributions of Howard Brooks and the strategic development of its dual-platform approach put the company on a promising path towards revolutionizing aging science. The initiative could unlock new therapeutic possibilities not only in aging but also in conditions such as cancer, neurological disorders, and organ failure, establishing Immorta Bio as a leader in longevity research.

About Immorta Bio

Immorta Bio Inc. is at the forefront of scientific longevity, concentrating on treating aging and its associated diseases. The company is committed to delivering groundbreaking therapies that challenge traditional perceptions of aging, bridged by its unique dual-platform strategy in senolytic immunotherapy and cellular rejuvenation.

For inquiries, media contact:
Boris N. Reznik, PhD
Chairman & CEO
+1 (305) 632-2939
[email protected]